Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell TAK and other ETFs, options, and stocks.

About TAK

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. 

CEO
Christophe Weber
CEOChristophe Weber
Employees
47,455
Employees47,455
Headquarters
Osaka, Osaka
HeadquartersOsaka, Osaka
Founded
1781
Founded1781
Employees
47,455
Employees47,455

TAK Key Statistics

Market cap
59.18B
Market cap59.18B
Price-Earnings ratio
75.75
Price-Earnings ratio75.75
Dividend yield
3.18%
Dividend yield3.18%
Average volume
3.13M
Average volume3.13M
High today
$18.83
High today$18.83
Low today
$18.46
Low today$18.46
Open price
$18.46
Open price$18.46
Volume
1.66M
Volume1.66M
52 Week high
$18.90
52 Week high$18.90
52 Week low
$12.99
52 Week low$12.99

TAK News

Nasdaq 1d
Axsome Inks Agreement To Obtain Exclusive Global Rights To TAK-063 From Takeda

(RTTNews) - Biopharmaceutical company Axsome Therapeutics, Inc. (AXSM) announced Wednesday that it has entered into an asset purchase agreement to obtain exclus...

Axsome Inks Agreement To Obtain Exclusive Global Rights To TAK-063 From Takeda
TipRanks 1d
Axsome Therapeutics enters TAK-063 asset purchase agreement with Takeda

Axsome Therapeutics (AXSM) announced that it has entered into an asset purchase agreement to obtain exclusive global rights to TAK-063, an oral, potent, and sel...

TipRanks 4d
Takeda’s Oral Psoriasis Drug Zasocitinib Shows Strong Phase 3 Results

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Analyst ratings

53%

of 15 ratings
Buy
53.3%
Hold
40%
Sell
6.7%

More TAK News

TipRanks 4d
Takeda announces new data from Phase 3 studies of TAK-279

Takeda (TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib, TAK-279, a next-generation, highly selective oral tyrosine kinase 2 inhibit...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.